Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.60 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812639 | 0.86 | P2RX1 (0.66) | P2RX1CDK1P2RX4P2RX7TAS1R3 | |
| SCHEMBL10305289 | 0.83 | CDK1 (0.56) | P2RX1CDK1SYKDNMT3APTGS1 | |
| SCHEMBL10305264 | 0.82 | CDK1 (0.55) | CDK1SYKDNMT3APTGS1MEN1 | |
| SCHEMBL13812600 | 0.81 | LTA4H (0.61) | CDK1SYKDNMT3APTGS1MEN1 | |
| SCHEMBL13812596 | 0.81 | THRB (0.58) | CDK1DNMT3APTGS1MEN1GAA | |
| SCHEMBL1154126 | 0.80 | TMPRSS4 (0.59) | P2RX1CDK1SYKDNMT3ACNR1 | |
| SCHEMBL10305273 | 0.79 | CDK1 (0.55) | CDK1SYKDNMT3APTGS1MEN1 | |
| SCHEMBL2987921 | 0.79 | NPC1 (0.75) | CNR1MEN1GAAKMT2AMAPT | |
| SCHEMBL1153954 | 0.78 | CDK1 (0.54) | CDK1SYKDNMT3APTGS1MEN1 | |
| SCHEMBL13812597 | 0.78 | THRB (0.58) | CDK1SYKDNMT3APTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151104-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140290-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | EIF2AK2, SARS1, ACE | P2RX1 3088/4885CDK1 3435/4885SYK 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.